Mp70-18 How Does Community-Level Social Vulnerability Affect Access to Prostate Cancer Clinical Trials? A Cross-Sectional Analysis

You have accessJournal of UrologyDiversity, Equity & Inclusion: Health Equity & Outcomes III (MP70)1 May 2024MP70-18 HOW DOES COMMUNITY-LEVEL SOCIAL VULNERABILITY AFFECT ACCESS TO PROSTATE CANCER CLINICAL TRIALS? A CROSS-SECTIONAL ANALYSIS Taseen F. Haque, Yash B. Shah, Lan Anh Galloway, Samuel Kovell, Bashir Al Hussein Al Awamlh, Daniel Joyce, Kelvin Moses, and Ruchika Talwar Taseen F. HaqueTaseen F. Haque , Yash B. ShahYash B. Shah , Lan Anh GallowayLan Anh Galloway , Samuel KovellSamuel Kovell , Bashir Al Hussein Al AwamlhBashir Al Hussein Al Awamlh , Daniel JoyceDaniel Joyce , Kelvin MosesKelvin Moses , and Ruchika TalwarRuchika Talwar View All Author Informationhttps://doi.org/10.1097/01.JU.0001008796.84999.75.18AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Patients from high poverty areas are underrepresented in prostate cancer (PCa) clinical trials. The effects of other variables such as community unemployment rates, housing costs and crowding have not been well studied. Social Vulnerability Index (SVI) is an assessment of four domains: socioeconomic status, household characteristics, racial/ethnic minority status, and housing type/transportation. Herein, we evaluate the association between U.S. county-level social vulnerability and availability of PCa clinical trials. METHODS: Linking data from ClinicalTrials.gov, the 2020 American Community Survey, and Centers for Disease Control and Prevention's SVI at the county level, we examined the availability of PCa trials in relation to SVI and county-level measures of elderly population, minority population, poverty, and insurance status. Counties were categorized by their SVI percentile score into low (0.0-0.33), moderate ((0.33-0.66]) and high ((0.66-1.0]) vulnerability. RESULTS: Between 4/2018 and 4/2023, 380 PCa trials were registered with 5927 trial sites (Table 1a). Clinical trial sites were more likely to be industry-sponsored in counties with moderate (OR 1.54, p<0.001) and high SVI (3.03, p<0.001). Counties with high socioeconomic vulnerability were least associated with presence of PCa trials and counties with higher proportions of racial and ethnic minority populations were most associated with presence of PCa trials. Presence of ≥1 PCa trial site was less likely in counties with greater proportions of persons older than 65 (OR 0.89, p<0.001), persons earning below 150% of the federal poverty line (FPL) (OR 0.92, p<0.001) and uninsured persons (OR 0.88, p<0.001). CONCLUSIONS: We identify several notable trends, including fewer overall trial sites but more industry-sponsored trial sites for in high-SVI counties. Additionally, areas with high socioeconomic vulnerability had fewer PCa trial sites, while those with larger minority populations had more trial sites. This data may inform future efforts to improve equitable access to PCa clinical trials. Source of Funding: N/A © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e1136 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Taseen F. Haque More articles by this author Yash B. Shah More articles by this author Lan Anh Galloway More articles by this author Samuel Kovell More articles by this author Bashir Al Hussein Al Awamlh More articles by this author Daniel Joyce More articles by this author Kelvin Moses More articles by this author Ruchika Talwar More articles by this author Expand All Advertisement PDF downloadLoading ...